Cat. No. 2601
Chemical Name: 17-(Cyclopropylmethyl)-4,14-dimetho
Biological ActivitySelective μ-opioid receptor antagonist (Ki values are 5.4, 244.6 and 2187 nM for μ-, δ- and κ-opioid receptors respectively). Reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Henry et al (2001) μ- and δ-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp.Neurol. 171 139. PMID: 11520128.
Marki et al (1999) μ-opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPγs binding assays. Eur.J.Pharmacol. 383 209. PMID: 10585536.
Schmidhammer et al (1995) Synthesis and biological evaluation of 14-alkoxymorphinans. 11. 3-hydroxycyprodime and analogues: opioid antagonist profile in comparison to cyprodime. J.Med.Chem. 38 3071. PMID: 7636870.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Cyprodime hydrochloride from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Cyprodime hydrochloride, supplier, Selective, μ-opioid, mu-opioid, antagonists, MOP, Receptors, OP3, Tocris Bioscience, μ Opioid Receptor Antagonist products
Find multiple products by catalog number
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.